Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 15/20 | 0.61 |
| ▸ | AKT3 | Q9Y243 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.35 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16794125 | 0.87 | BTK (0.67) | BTKAKT3RAB9ANPC1TP53 | |
| SCHEMBL20461146 | 0.86 | BTK (0.64) | BTKAKT3RAB9ANPC1ROCK2 | |
| SCHEMBL16794298 | 0.84 | BTK (0.63) | BTKAKT3 | |
| SCHEMBL16794439 | 0.84 | BTK (0.63) | BTKAKT3RAB9ANPC1ROCK2 | |
| SCHEMBL16794170 | 0.83 | BTK (0.62) | BTKAKT3RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL16794476 | 0.83 | BTK (0.62) | BTKAKT3 | |
| SCHEMBL16793953 | 0.82 | BTK (0.63) | BTKAKT3ROCK2ROCK1 | |
| SCHEMBL16794217 | 0.78 | BTK (0.60) | BTKAKT3 | |
| SCHEMBL16794199 | 0.77 | BTK (0.53) | BTKAKT3RAB9ANPC1TP53 | |
| SCHEMBL20026922 | 0.76 | BTK (0.56) | BTKAKT3RAB9ANPC1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3080103-B1 | BIARYL COMPOUNDS USEFUL FOR THE TREATMENT OF HUMAN DISEASES IN ONCOLOGY, NEUROLOGY AND IMMUNOLOGY | BIOGEN MA INC (US) | 2018-04-18 | — | — | EP | disclosed |